Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)1.09M
Market Cap
$27.24M
Enterprise Value-$4.32B
Total Cash (Recent Filing)$10.12B
Total Debt (Recent Filing)$78.54M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding11,254,697
10 Day Avg. Volume342,221
30 Day Avg. Volume1,088,816
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-158.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit943.65K
Enterprise Value/Ebitda242.64
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation — LP-184 Phase IaRobust Phase Ia results constitute durable program de-risking: a 48% clinical benefit rate supports biologic plausibility, strengthens go/no-go decisions, enhances partner interest, and increases probability of advancing to later-stage trials that can unlock regulatory and commercial value over months to years.
AI Platform Commercial Readiness (withZeta.ai / RADR)Commercial-ready AI tools create a structural revenue pathway distinct from drug approvals: licensing and subscription models can generate recurring, scalable income, bolster partner relationships, and improve trial efficiency—enhancing long-term viability even as clinical programs progress.
Low Leverage And Enlarged 2025 Capital BaseVery low debt reduces refinancing risk and preserves flexibility to fund R&D or negotiate partnerships. The larger 2025 asset/equity base provides a stronger capital platform to support trials and commercialization efforts, improving resilience versus highly leveraged peers.
Bears Say
No Revenue And Persistent LossesAbsence of product revenue means the business depends on milestone payments, licensing, or capital raises. Persistent, material losses imply the company cannot self-fund growth; long-term sustainability hinges on successful commercialization or partnerships, elevating execution risk.
Rising Operating Cash BurnEscalating cash burn shortens optionality: it accelerates the timing of financing needs, increases likelihood of dilutive capital raises, and forces tighter prioritization of programs, which can delay development timelines and reduce the firm's ability to sustain multiple parallel initiatives.
Near-term Funding Requirement / Limited RunwayA short runway creates immediate strategic pressure: the company may have to secure partnerships, license deals, or dilutive financing on accelerated timelines, which can alter program priorities, compress negotiating leverage, and risk interruption of clinical and commercialization plans.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $27.24M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is May 05, 2026 which is in 15 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on Mar 30, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.1.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 11,254,697 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 10.931%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
19.12% Insiders
3.77% Mutual Funds
0.21% Other Institutional Investors
73.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---